Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Melody® Transcatheter Pulmonary Valve Post-Approval Study

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Medtronic Cardiovascular ( Medtronic Heart Valves ) Identifier:
First received: August 20, 2010
Last updated: April 29, 2016
Last verified: April 2016
The purpose of this study is to confirm the short-term hemodynamic effectiveness results achieved by real-world providers are equivalent to the historical control established in the IDE study.

Condition Intervention
Dysfunctional RVOT Conduit
Device: Melody® Transcatheter Pulmonary Valve

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Implantation of the Medtronic Melody Transcatheter Pulmonary Valve (TPV) in Patients With Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduits: A Post-Market Approval Study

Further study details as provided by Medtronic Cardiovascular:

Primary Outcome Measures:
  • Acceptable TPV hemodynamic function at six months after successful TPV implantation [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • % of patients with procedural success [ Time Frame: 5 year ] [ Designated as safety issue: No ]
  • % of subjects with serious procedural adverse events [ Time Frame: 5 year ] [ Designated as safety issue: No ]
  • % of subjects with serious device-related adverse events at six months post-implant [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Incidence of serious device-related adverse events over the follow-up period [ Time Frame: 5 year ] [ Designated as safety issue: No ]
  • Freedom from stent fracture [ Time Frame: 5 year ] [ Designated as safety issue: No ]
  • Freedom from reintervention on the TPV [ Time Frame: 5 year ] [ Designated as safety issue: No ]
  • Freedom from RVOT conduit reoperation [ Time Frame: 5 year ] [ Designated as safety issue: No ]
  • Freedom from death (all-cause, procedural, and device-related) [ Time Frame: 5 year ] [ Designated as safety issue: No ]
  • Changes in NYHA functional classification [ Time Frame: 5 year ] [ Designated as safety issue: No ]

Enrollment: 131
Study Start Date: July 2010
Estimated Study Completion Date: July 2017
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Melody TPV Implant
Melody® Transcatheter Pulmonary Valve implanted into a dysfunctional RV-PA Conduit.
Device: Melody® Transcatheter Pulmonary Valve
Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVPA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
Other Name: Melody Transcatheter Pulmonary Valve


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Existence of a full (circumferential) RVOT conduit that was equal to or greater than 16 mm in diameter when originally implanted
  • Dysfunctional Right Ventricular Outflow Tract conduits with a clinical indication for interventions (regurgitation ≥ moderate regurgitation, Stenosis: mean RVOT gradient ≥ 35 mmHg)

Exclusion Criteria:

  • Implantation in the aortic or mitral position
  • Venous anatomy unable to accommodate a 22-fr size introducer sheath
  • Obstruction of the central veins
  • Clinical or biological signs of infection including active endocarditis
  • Unwilling or unable to provide written informed consent or comply with the follow-up requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01186692

United States, California
Rady Children's Hospital
San Diego, California, United States, 92123
United States, Illinois
Advocate Hope Children's Hospital
Oak Lawn, Illinois, United States, 60453
United States, Michigan
CS Mott Children's Hospital, University of Michigan
Ann Arbor, Michigan, United States, 48109
Children's Hospital of Michigan
Detroit, Michigan, United States, 48201
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Missouri
St. Louis Children's Hospital
St. Louis, Missouri, United States, 63110
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15201
United States, Texas
Children's Medical Center Dallas, UT Southwestern
Dallas, Texas, United States, 75235
United States, Utah
Primary Children's Medical Center, University of Utah
Salt Lake City, Utah, United States, 84113
Sponsors and Collaborators
Medtronic Heart Valves
Principal Investigator: Jaqueline Kreutzer, MD Children's Hospital of University of Pittsburgh Medical Center